|
Prothena Corporation Public Limited Company (NASDAQ: PRTA) |
|
Prothena Corporation Public Limited Company
PRTA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Prothena Public Limited growth rates, revenue grew
by 5556 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 14
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.43 %
Prothena Public Limited net loss decreased from $-72 millions, to $-60 millions in first quarter of 2025,
• More on PRTA's Growth
|
|
Prothena Public Limited realized a net loss in trailing twelve months.
Prothena Public Limited realized cash reduction of $ -2.41 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.24.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.32.
• More on PRTA's Valuation
|
|
|
|
|
Prothena Public Limited realized net loss in trailing twelve months.
Prothena Public Limited realized cash outflow of $ -2.41per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.24.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.32.
Prothena Public Limited Price to Book Ratio is at 0.71 lower than Industry Avg. of 34.08. and higher than S&P 500 Avg. of 0.01
• More on PRTA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com